§Bortezomib was
originally made in 1995 at Myogenics.
§Bortezomib is
also FDA-approved for use in the treatment of multiple myeloma & mantle
cell Lymphoma.
§Bortezomib is a
dipeptide Boronic acid derivative and proteasome inhibitor used to treat
multiple myeloma and mantle cell lymphoma.
§Bortezomib has a
role as an antineoplastic
agent, a
proteasome inhibitor, a protease
inhibitor and
• an antiprotozoal
drug.
•Proteasomes
are in cells. They help to break down proteins that the cell doesn't need.
Bortezomib b blocks the
proteasomes so the proteins build up inside the cell. The cell then dies.
§A reversible
inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus
and cytosol of all eukaryotic cells.
•Bortezomib delays
tumor growth and enhances the cytotoxic effects of radiation and chemotherapy. 
Reference Standards | Research Chemicals | Research Services
